Abstract:Introduction Agitation is reported in up to 70% of individuals with Alzheimer's disease (AD) and is characterized by emotional distress, aggressive behaviors, disruptive irritability and disinhibition. Agitation is associated with increased caregiver burden, decreased functioning, accelerated cognitive decline, earlier nursing home placement, and increased mortality. AXS-05 (dextromethorphan-bupropion) is a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist approved for the treatment of major depressive disorder and under evaluation for Alzheimer's disease-related agitation (ADA). Methods ACCORD (Assessing Clinical Outcomes in Alzheimer's Disease Agitation; NCT04797715) was a Phase 3, randomized, discontinuation, double-blind, placebo-controlled, multi-center trial to evaluate efficacy and safety of AXS-05 in individuals with ADA. Participants with a diagnosis of probable AD and clinically meaningful agitation were enrolled into a 9-week, open-label period during which they were treated with AXS-05 and monitored for sustained clinical response defined as a ≥30% improvement from baseline in the Cohen Mansfield Agitation Inventory (CMAI) total score and improvement on the Patient Global Impression of Change (PGI-C; score of ≤3) that were both maintained for at least 4 consecutive weeks. Participants who experienced a sustained clinical response during the open-label period were then randomized (1:1) to continue treatment with AXS-05 or placebo in a double-blind fashion for up to 26 weeks. Treatment was continued until either a relapse of agitation symptoms or the end of the double-blind period, whichever occurred first. The primary endpoint in the study was time from randomization to relapse of agitation. The key secondary endpoint was the percentage of participants who relapsed. Results 178 individuals were enrolled into the open-label period and treated with AXS-05 (mean CMAI total score at baseline = 70.9). Statistically significant improvement on the CMAI was seen with open-label AXS-05 treatment at all timepoints starting at Week 1 (P<.001) with mean reductions from baseline of 6.7 points at Week 1 and 20.6 points at Week 5 (P<.001). In the randomized discontinuation phase of the trial, 108 participants were randomized to continue AXS-05 (n=53) or switched to placebo (n=55). AXS-05 met the primary endpoint by substantially delaying the time to relapse of agitation symptoms as compared to placebo, with a hazard ratio for time to relapse of 0.275 (P=.014), representing a 3.6-fold lower risk of relapse compared to placebo. AXS-05 also met the key secondary endpoint of relapse prevention (7.5% relapse incidence rate for AXS-05; 25.9% for placebo, P=.018). The rates of adverse events observed in the double-blind period were 28.3% AXS-05, 22.2% placebo. Discontinuations due to adverse events were 0% AXS-05, 1.9% placebo. There was no evidence of cognitive decline for participants treated with AXS-05. AXS-05 was not associated with sedation. Conclusions ACCORD met its primary outcome as treatment with AXS-05 substantially reduced the risk of relapse and was generally well-tolerated for participants who achieved sustained clinical response in the preceding open label treatment period. These data support the continued development of AXS-05 as an efficacious and safe novel treatment for ADA.

ACETOPHENAZINE (TINDAL) IN THE TREATMENT OF 80 CHRONICALLY ILL PATIENTS WITH ANXIETY AND TENSION: DOUBLE‐BLIND STUDY

Acupoint Transcutaneous Electrical Nerve Stimulation in Hospitalized COPD Patients with Severe Dyspnoea: A Randomized Controlled Trial

Efficiency of Acupuncture and Transcutaneous Electroneurostimulation in Treatment of Patients with Anxiety Disorders

Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia

Add-On Treatment with Passiflora incarnata L., herba, during Benzodiazepine Tapering in Patients with Depression and Anxiety: A Real-World Study

The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders

Citalopram for agitation in Alzheimer's disease: design and methods

[Recent experience in the short-term etizolam treatment of irritable colon syndrome]

A Comparison of the Anxiolytic Properties of Tofisopam and Diazepam: A Double-Blind, Randomized, Crossover, Placebo-Controlled Pilot Study

Passiflora incarnata L., herba, in benzodiazepine tapering: long-term safety and efficacy in a real-world setting

[Use of tiapride in the anxious alcoholic]

Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial

Electroacupuncture and acupuncture in the treatment of anxiety - A double blinded randomized parallel clinical trial

Efficacy and Safety Of AXS-05 in Agitation Associated with Alzheimer's Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Trial

Comparison of tandospirone and escitalopram as a symptomatic treatment in Multiple System Atrophy-cerebellar ataxia: An open-label, non-controlled, 4 weeks observational study

Targeted Sleep Enhancement Reduces Residual Anxiety Symptoms in Peri-Adolescents Previously Treated for Anxiety Disorders

Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial

Effects of Tandospirone Augmentation in Major Depressive Disorder Patients with High Anxiety: A Multicenter, Randomized, Parallel-Controlled, Open-Label Study

Lack of Acute Agomelatine Effect in a Model of Social Anxiety in Healthy Volunteers: A Double-Blind, Placebo-Controlled Trial

Child/Adolescent Anxiety Multimodal Study: Evaluating Safety

Clinical Evaluation of the Efficacy and Safety of Tandospirone Versus Sertraline Monotherapy for Social Anxiety Disorder: a Randomized Open‐label Trial